Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.
Mary Beth Dameron, PharmD, BCACP
Advertisement
Articles by Mary Beth Dameron, PharmD, BCACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy
2
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
3
New Data Show Elinzanetant Is a Safe, Well-Tolerated Non-Hormonal Therapy for Menopausal Vasomotor Symptoms
4
Hormone Therapy Use, Understanding, and Perceptions Have Positively Shifted From 2021 to 2025
5
